Canine
Update (June 12, 2026): Grapiprant-Based Multimodal Management in Young Dogs with OA
TL;DR
A 4-month open-label study of 48 dogs under 4 years of age found that a standardized multimodal regimen anchored on grapiprant produced significant improvements in owner-assessed pain scores and objective gait measures.
What just dropped
- Enomoto M et al. Response to treatment with grapiprant as part of a standard multimodal regimen in young dogs with appendicular joint osteoarthritis associated pain. Front Vet Sci. 2024;11:1461628. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1461628/full — 48 dogs aged 9 months to 4 years with radiographic OA in one or more appendicular joints, treated with grapiprant at the approved daily dose, omega-3 fatty acid supplementation, and graduated leash exercise for 4 months. Liverpool OsteoArthritis in Dogs (LOAD) and sleep-disturbance scores (SNoRE) both improved significantly (p<0.001) over time and at each monthly timepoint. Peak vertical force on force plate increased significantly (p<0.001). Minimal clinically important differences in LOAD were achieved in 42 to 54 percent of dogs each month. Overall compliance was 97 percent of target doses administered. Gastrointestinal adverse events were in line with expectations for NSAIDs.
- Cassemiche A et al. [via BSAVA pain management summary, September 2024] https://www.bsava.com/article/whats-new-in-pain-management-and-analgesic-research/ — complementary randomized, double-blinded trial of grapiprant vs. meloxicam for 14 days following TPLO in 48 dogs. Grapiprant-treated dogs had lower pain interference scores at day 3 and day 10, lower pain severity scores at day 3, better owner-assessed quality of life, and a significant improvement in veterinarian-assessed orthopedic recovery at 15 days.
Context
Grapiprant's pivotal field study enrolled predominantly middle-aged to older dogs with chronic OA. The Enomoto cohort addresses an underserved population: young adults with radiographic OA, commonly associated with breed-related joint dysplasia. Hips, elbows, and stifles were the joints most frequently affected in the 48-dog cohort. Most dogs had two or more affected joints.
The study had no placebo comparator, but objective force plate data corroborated the subjective CROM improvements. The investigators note that young dogs rarely have a single-limb lameness, complicating gait analysis—an important caveat when applying the data to clinical decisions.
What this changes in Grapiprant (Galliprant) for Canine Osteoarthritis Pain (https://www.thevoyage.ai/forvets/knowledge/grapiprant-canine-osteoarthritis-pain)
The existing evergreen page discusses grapiprant evidence primarily in adult dogs with established OA. The Enomoto 2024 data supports extending consideration to younger dogs with early-onset or breed-related joint OA, where the label indication applies but clinical trial data were previously limited. Clinicians managing elbow dysplasia, hip dysplasia, or post-developmental-disease OA may find this 4-month outcome data directly relevant when counseling owners on long-term management.
Voyage Clinical Desk
From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-12-grapiprant-young-dogs-multimodal
References
- Enomoto M et al. Response to treatment with grapiprant as part of a standard multimodal regimen in young dogs with appendicular joint osteoarthritis associated pain. Front Vet Sci. 2024;11:1461628. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1461628/full
- Cassemiche A et al. Comparison of grapiprant and meloxicam for management of postoperative joint pain in dogs: A randomized, double-blinded, prospective clinical trial. J Vet Intern Med. 2024;38(4):2324-2332. [via BSAVA] https://www.bsava.com/article/whats-new-in-pain-management-and-analgesic-research/
Changelog
- 2026-06-12: First published.
Related reads
References
More clinical updates
Update (June 13, 2026): Bedinvetmab Produces Equivalent OA Pain Control With Fewer Adverse Events Than Meloxicam in Head-to-Head RCT
A 101-dog RCT finds bedinvetmab and meloxicam produce equivalent COI reductions; bedinvetmab had 4 AEs vs 17 for meloxicam (9 GI), with more completers.
Read →Update (June 13, 2026): Lokivetmab Maintains Pruritus Control in 87% of Dogs Across 12 Months — Cohort Data
Gober 2025 (n=75): 87% of dogs maintained PVAS below Day 0 baseline throughout 12 months; 93% owner satisfaction, 86% planning to continue lokivetmab.
Read →Update (June 13, 2026): Robenacoxib Reduces Owner-Assessed Disability 49% and Improves Activity Counts in Cats With DJD
Adrian 2021: 49% disability reduction (p=0.01), objective activity gain p=0.046 at 3 wks. Pisack 2024: non-inferior to grapiprant perioperatively.
Read →Update (June 13, 2026): First Multicenter RCT Comparing Imepitoin to Phenobarbital in Cats With Idiopathic Epilepsy — Responder Rates and AE Profile
Charalambous 2026 RCT (n=37 cats): imepitoin 62% responder rate (P=0.028, 6.1→3.0/month) vs phenobarbital 90%. AE rates 88% vs 90%.
Read →